FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch

Today's Daily Dose brings you news about BioLineRx's promising phase II pancreatic adenocarcinoma trial results; FDA's new decision date for Bristol-Myers Squibb's Opdivo plus low-dose Yervoy sBLA; Dynavax Technologies' SYNERGY-001 study results; Genmab's promising results from phase III CASSIOPEIA study, and Leap's promising esophagogastric cancer trial results.

from RTT - Biotech https://ift.tt/2yo5X1R
via IFTTT